深部左心室辅助装置感染的治疗结局
驱动线感染和因出血再次探查与DDI发生相关;主要病原体为铜绿假单胞菌(19%)和耐甲氧西林金黄色葡萄球菌(13%)。因装置感染行心脏移植者5年生存率优于未移植者(80% vs 11%,P=0.01),但25%(3例)发生深部胸骨伤口感染。
要点
- 驱动线感染和因出血再次探查与深部装置感染发生相关。
- 因装置感染行心脏移植者5年生存率为80%,未移植者为11%(P=0.01);移植后25%(3例)发生深部胸骨伤口感染。
核心结论
- 深部装置感染在目的地治疗时代是罕见但具有挑战性的并发症。
- 对符合条件的患者,心脏移植是首选的管理策略,但感染性并发症常见。
研究设计与样本
- 回顾性研究,纳入2004年1月至2021年6月在本中心接受HeartMate 2(Abbott)或HeartMate 3(Abbott)植入式左心室辅助装置植入的658例患者。
- 深部装置感染依据影像学和临床标准定义;累积发生率采用Fine-Gray子分布模型计算;生存分析采用Kaplan-Meier法。
主要发现
- 研究期间共发生32例(4.8%)深部装置感染。
- 驱动线感染和因出血再次探查与深部装置感染的发生相关。
- 深部装置感染的主要病原体为铜绿假单胞菌(19%)和耐甲氧西林金黄色葡萄球菌(13%)。
- 32例深部装置感染患者中,19例(59%)接受装置更换,6例(19%)接受初始移植,7例(22%)仅接受清创和抗生素治疗。
关键数值与推荐
- 接受装置更换的患者中,12例(63%)新装置发生再感染,6例随后接受心脏移植。
- 因装置感染接受心脏移植的患者5年生存率改善(80% vs 11%;P=0.01)。
- 心脏移植后3例(25%)发生深部胸骨伤口感染。
临床怎么用
- 作者认为,对符合条件的患者,心脏移植是深部装置感染的首选管理策略。
- 作者指出,心脏移植后感染性并发症常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Among left ventricular assist device patients, the most commonly infected component is the drive line, which can be managed with antibiotics and local debridement. Infection of intrathoracic device components is less common but more difficult to manage. Herein we describe the incidence of deep device infection (DDI) at our center as well as management and outcomes. METHODS: We retrospectively reviewed 658 patients who underwent implantable left ventricular assist device insertion with HeartMate 2 (Abbott) or HeartMate 3 (Abbott) devices between January 2004 and June 2021. DDI was defined according to radiographic and clinical criteria. Cumulative incidence was calculated using a Fine-Gray subdistribution model; survival analysis was performed using the method of Kaplan and Meier. RESULTS: There were 32 (4.8%) DDIs during this study period. Drive line infection and re-exploration for bleeding were associated with development of DDI. Cumulative incidence of DDI increased over time, affecting 11% (7%-18%) at 5 years. The dominant microbes involved in DDI were Pseudomonas aeruginosa (19%) and methicillin-resistant Staphylococcus aureus (13%). Nineteen patients (59%) with device infection underwent device exchange, 6 (19%) underwent initial transplant, and 7 (22%) were treated solely with debridement and antibiotics. Of those who underwent device exchange, 12 (63%) developed reinfection of their new device and 6 underwent subsequent heart transplant. Patients who underwent transplantation for management of device infection had improved 5-year survival (80% vs 11%; P = .01) but 3 patients (25%) developed deep sternal wound infection after transplant. CONCLUSIONS: DDI is a rare but challenging complication in this destination era. Heart transplantation is the preferred management strategy for eligible patients but infectious complication is common.
引用
- Simpson MT, Ning Y, Kurlansky P, et al. Outcomes of treatment for deep left ventricular assist device infection. J Thorac Cardiovasc Surg. 2022. PMID: 36280430. doi:10.1016/j.jtcvs.2022.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。